Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
What is the ticker symbol for Cabaletta Bio Inc? What does CABA stand for in stocks?
CABA is the stock ticker symbol of Cabaletta Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Cabaletta Bio Inc (CABA)?
As of Fri Nov 22 2024, market cap of Cabaletta Bio Inc is 91.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of CABA stock?
You can check CABA's fair value in chart for subscribers.
Is Cabaletta Bio Inc a good stock to buy?
The fair value guage provides a quick view whether CABA is over valued or under valued. Whether Cabaletta Bio Inc is cheap or expensive depends on the assumptions which impact Cabaletta Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CABA.